Is it time to trade in BMI for body roundness? GPs need to move away from using BMI as a diagnostic tool, one expert in the field says. So how should patients’ weight risks be calculated?
Mounjaro expanded to include weight management The TGA has approved tirzepatide for the treatment of overweight and obesity for those with comorbidities, via private prescription.
Study links semaglutide and suicidal ideation risk There are calls for urgent investigation into its impact on mental health, but GPs are urging caution when interpreting the research.
Wegovy launches in Australia The manufacturer assured GPs supply planning has been its priority amid critical Ozempic shortages, but concerns remain over Wegovy’s availability.
Mounting evidence for sugar tax success Daily sugar intake fell by 11 g in adults one year after the UK rolled out a levy, as calls to introduce the tax in Australia gain momentum.
Holistic patient care key for overweight and obesity New education for GPs supporting patients with overweight and obesity aligns with the latest Red Book recommendations.
Body fat over BMI for obesity diagnosis: Study Researchers say doctors must ditch BMI as a diagnosis tool as it is excluding patients in need, instead calling for the use of waist-to-height ratios.
Sugary drink tax could raise billions: Parliamentary Budget Office Data has shed light on the significant economic benefits a proposed 20% levy could have, while GPs spruik its potential health benefits.
‘Absolutely tiny’ Federal obesity funding challenged Questions have been raised about why no weight loss drugs are on the PBS, as research highlights the lack of funding for obesity prevention.
Semaglutide shortage sparks patient demands for alternatives But in Australia, the new drug generating the most interest is still in its infancy – and not yet listed on the PBS.